Company Overview
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Why Investors Should Care
Generates a return on equity of 19.9%, reflecting efficient use of shareholder capital.
Maintains a net profit margin of 53.9%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $389.13M (+33.9% YoY); net profit $204.83M.
- Trailing 12 Months Year-on-year growth — revenue +31.9%, earnings +52.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 31.90% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 52.50% |
Stock Price Performance
| 1 Year: | +132.86% |
| 6 Months: | +28.70% |
| 3 Months: | +29.72% |
| 1 Month: | +10.15% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)51.26 · Neutral
P/E of 46.89 is above the sector median of 25.88 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 53.9%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KRYS Krystal Biotech, Inc. R2K | 350.24 | 46.89 | $10.32B | 0.00% | 13.10% | 19.90% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 8.56M | 45.25M | 70.28M | 83.84M | 88.18M | 96.04M | 97.80M | 116.36M |
| Operating Income | -322.00K | -465.00K | -715.00K | -2.09M | -2.28M | -2.45M | -2.97M | -4.69M | -5.89M | -5.34M | -5.95M | -6.95M | -9.68M | -14.35M | -16.39M | -15.65M | -50.22M | -28.75M | -31.45M | -48.82M | -38.05M | -25.99M | -6.68M | 8.57M | 22.47M | 36.25M | 39.31M | 41.37M | 53.69M |
| Net Income | -322.00K | -494.00K | -759.00K | -5.27M | -2.15M | -2.28M | -2.75M | -4.11M | -5.35M | -4.27M | -5.34M | -6.83M | -9.61M | -15.81M | -16.36M | -15.59M | -49.97M | -28.11M | -29.85M | -45.30M | -33.21M | 80.75M | 932.00K | 15.57M | 27.18M | 35.73M | 38.33M | 79.36M | 55.93M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -0.37 | -0.49 | -0.74 | -0.74 | -0.70 | -1.99 | -1.10 | -1.17 | -1.76 | -1.25 | 2.79 | 0.03 | 0.53 | 0.91 | 1.20 | 1.29 | 2.66 | 1.83 |
| R&D Expense | 241.00K | 319.00K | 446.00K | 1.35M | 1.52M | 1.52M | 1.91M | 3.17M | 4.22M | 3.88M | 3.52M | 3.64M | 5.10M | 6.20M | 6.59M | 6.08M | 9.31M | 10.89M | 11.52M | 12.29M | 12.14M | 10.63M | 10.96M | 15.58M | 13.51M | 14.26M | 14.41M | 14.59M | 15.33M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 0 | 0 | 50.70M | 290.51M | 389.13M |
| Operating Income | -1.14M | -4.77M | -11.92M | -22.08M | -33.00M | -68.28M | -145.20M | -109.62M | 65.75M | 161.29M |
| Net Income | -1.15M | -7.92M | -10.89M | -19.09M | -32.17M | -69.57M | -139.97M | 10.93M | 89.16M | 204.83M |
| Diluted EPS | - | - | - | - | -1.71 | -3.13 | -5.49 | 0.39 | 3.00 | 6.84 |
| R&D Expense | 741.00K | 3.21M | 7.76M | 15.62M | 17.94M | 27.88M | 42.46M | 46.43M | 53.58M | 58.05M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Aug 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 2.18M | - | 50.11M | 116.12M | 209.02M | 310.84M | - | 558.45M | 818.36M | 1.06B | 1.33B |
| Current Assets | - | - | - | - | - | - | - | 383.78M | 587.91M | 742.04M | 1.02B |
| Cash & Equivalents | 1.92M | - | 49.59M | 103.67M | 187.51M | 268.27M | - | 161.90M | 358.33M | 344.87M | 496.30M |
| Inventory | - | - | - | - | - | - | - | 0 | 6.99M | 26.51M | 40.48M |
| Receivables | - | - | - | - | - | - | - | 0 | 42.04M | 104.75M | 127.42M |
| Total Liabilities | 1.89M | - | 640.00K | 2.89M | 6.11M | 18.76M | - | 36.22M | 39.71M | 109.46M | 114.23M |
| Current Liabilities | 43.00K | - | 640.00K | 2.60M | 3.33M | 15.45M | - | 28.85M | 33.09M | 102.00M | 102.94M |
| Long Term Debt | - | 4.25M | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | 8.93M | 8.09M | 7.26M | 9.34M |
| Total Equity | 289.00K | - | 49.47M | 113.23M | 202.91M | 292.08M | - | 522.23M | 778.64M | 946.38M | 1.22B |
| Shares Outstanding | - | - | - | - | - | - | - | 25.76M | 28.24M | 28.79M | 29.19M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -9.45M | -18.69M | -26.08M | -47.94M | -100.57M | -88.80M | 123.42M | 200.87M |
| Investing Cash Flow | - | - | -10.32M | -4.99M | -11.18M | -226.77M | -114.08M | 82.64M | -163.44M | -58.42M |
| Financing Cash Flow | - | - | 73.85M | 107.53M | 118.02M | 347.69M | 35.35M | 202.75M | 27.01M | 8.71M |
| Capital Expenditure | -15.00K | -210.00K | -2.23M | -6.40M | -14.84M | -68.34M | -52.98M | -11.80M | -4.24M | -11.95M |
| Free Cash Flow | - | - | -11.68M | -25.09M | -40.93M | -116.27M | -153.55M | -100.60M | 119.18M | 188.91M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | -216.2% | 22.6% | 41.5% |
| Net Margin % | - | - | - | - | - | - | - | 21.6% | 30.7% | 52.6% |
| ROE % | -397.9% | -16.0% | -9.6% | -9.4% | -11.0% | - | -26.8% | 1.4% | 9.4% | 16.8% |
| ROCE % | -53.4% | -9.6% | -10.5% | -10.7% | -11.2% | - | -27.4% | -14.0% | 6.9% | 13.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.84% | 4.37M | $1.48B |
| 2 | Blackrock Inc. | 13.37% | 3.94M | $1.34B |
| 3 | Avoro Capital Advisors LLC | 9.80% | 2.89M | $979.25M |
| 4 | Vanguard Portfolio Management LLC | 4.94% | 1.46M | $493.79M |
| 5 | State Street Corporation | 4.46% | 1.31M | $445.55M |
| 6 | Vanguard Capital Management LLC | 3.95% | 1.17M | $395.01M |
| 7 | Soleus Capital Management, L.P. | 3.91% | 1.15M | $390.86M |
| 8 | Capital World Investors | 2.80% | 824.72K | $279.56M |
| 9 | Redmile Group, LLC | 2.28% | 673.50K | $228.30M |
| 10 | Geode Capital Management, LLC | 2.18% | 643.98K | $218.29M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KRYS
KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism - Stocktwits
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxPZ0NrR1ZIM1I5Uml4MWR0OFZ0b2JtSi1tRUZnY3hMcDRHaU5Ed1hGelZSQ0Jzci1QcF9mNjVoVEE0dDZ5aERkSC1IdW5rVjktbmJBZXFpLUVwM3Y4Y0RLejhMQVpVUUwxSFRRc2ZCT0p4SmE2Qy1IM2pJSW1YTWdWZzZrS2tQbVozNDV1UU…
Krystal Biotech (KRYS) Soars 3.4%: Is Further Upside Left in the Stock? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNV2t2QmRNaEktbWdTYTRseFZqRHE3NFV5Y1JHSGtaVFJIYi1Qd3hERUpzLU9hSzVISjVYdjE5NGlKN2VqZTRxWGFWSzZOclR3ek1iWkpTYURvdHpERWFXZDVOMnFpVy1jVlZQam1IVVJ5SGx4NHZ5NkJoMEt4RXdaMGJCdHhVaGVra0MwTX…
Is Krystal Biotech (KRYS) Too Expensive After A 440% Return? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxOeG1JZlk1bEItOC0tbHdfVGpyOWhLakV1anA4RVR5NUdTdEVwVTdFVlJWbC0zQ1IwdmhNU3hfTXN5MzJJU29fS3dzN09JY1g5cjBLMVAtbGRrVW41VFA3aVV1RG8zdUZuMThhUGJEcUFLUmdQVW50czc0Yzh4R1hYenBuT19vWDcyeDdyNH…
Krystal Biotech, Inc. Stock 12‑Month Price Target Raised to $369.44, Implies 1% Upside - TradingView
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxNSXVVOUVXMzEzNmtxdlZvRGt1dUpTU2xWQVVwM24xb2szWGgtcS1GbG1wbVZ0QlNvdWo1eEUxVmQxWjZnMUc4bjJ4MEZFYnRNb3F5NE9DbWVNYzJEZE1VamhTWlBFVG5xVFAxSEhYV0RNS1pSY1k5QnJCWnVEbFlEZnlneXhWeDZFYk4xYl…
Krystal Biotech, Inc. (KRYS) Stock Analysis: Evaluating the 31.9% Revenue Growth and Its Implications for Investors - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxPMlcyNVFSSG5NMGlxNDNzX0VzNEk4aUdpbFRkT3YyQzM2NlpBeks3QVRNNGc3cmRHOGRnZzRNY244SUt2clBrS1E0UHVvY3BtWTN4UGpCcjlDdWhrMUlJdzFQUTFfb0ZEYXJBR2RIZnRXX1F4REZ3OG9IR1NxVjlsZ0hQMUdCQWFoWDFNcF…
3 Biotech Firms With Major Potential Catalysts in the Coming Months - MarketBeat
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPclp0UFdTTUJadkpfU1NzeWZHaDdMZEw4ZDY3U0FPSFdpZUNKcXFtcm9wQ1Y1b0VBUmFKYk9QUHo4VmlyaG1xcnFMWlc0WDZCaGdrSVNSVGlZWVlzUlVjQnl1XzhyU3dDYzBQa3dta1p3UHUzeHpUSjJuZmp3OTRzZTAtcVQyWVBMWi1rQ2…
KRYS — Frequently Asked Questions
What is the current share price of Krystal Biotech, Inc. (KRYS)?
As of 2026-07-15 16:51 PDT, Krystal Biotech, Inc. (KRYS) trades at $350.24 on NasdaqGS. Its 52-week range is $134.94 to $378.15.
What is the market capitalisation of KRYS?
Krystal Biotech, Inc. (KRYS) has a market capitalisation of $10.32B on NasdaqGS.
What is the P/E ratio of KRYS?
KRYS trades at a trailing price-to-earnings (P/E) ratio of 46.89. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 7.82.
What is the return on equity (ROE) of KRYS?
KRYS has a return on equity (ROE) of 19.90%. Its return on capital employed (ROCE) is 13.10%.
Is KRYS a good stock to buy?
This page provides a data-driven analysis of Krystal Biotech, Inc. (KRYS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.